Markers of Disease Activity in Multiple Sclerosis

Information

  • Research Project
  • 6883803
  • ApplicationId
    6883803
  • Core Project Number
    R43NS051035
  • Full Project Number
    1R43NS051035-01
  • Serial Number
    51035
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/2004 - 20 years ago
  • Project End Date
    8/31/2005 - 19 years ago
  • Program Officer Name
    UTZ, URSULA
  • Budget Start Date
    9/30/2004 - 20 years ago
  • Budget End Date
    8/31/2005 - 19 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/30/2004 - 20 years ago

Markers of Disease Activity in Multiple Sclerosis

[unreadable] DESCRIPTION (PROVIDED BY APPLICANT): Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. Most patients initially have a relapsing-remitting course in which they experience intermittent clinical exacerbations of the disease and, over time, a gradual deterioration in neurological function. Physicians monitor MS patients by physical exam supplemented by MRI. These tests have limited predictive value. There is a need for a simple test that can predict a patient's future course, both exacerbations and response to treatment. A predictive test would allow possible early intervention before significant neurological deterioration has occurred or adjustment of medications that are/ are not effective. Source Precision Medicine has performed extensive work on gene expression profiles in normal and in patients with inflammation- and immune-related diseases and has developed a system for high-precision molecular analysis that can be performed in small quantities of whole blood. The objective of Phase I is to evaluate the specific diagnostic potential of a panel of candidate gene loci. The specific aims of the proposed research are to: 1) Demonstrate a characteristic pattern of gene expression in the whole blood of patients with MS; 2) Correlate changes in gene expression in blood samples from MS patients with clinical parameters and indices; and 3) Identify a subset of genes that can be used to monitor flares or exacerbations of MS and that may be involved in the disease process. The overall objective of this research is to develop a commercial analytical tool that can be used for diagnosis and evaluation of MS. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SOURCE PRECISION MEDICINE
  • Organization Department
  • Organization DUNS
  • Organization City
    BOULDER
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    80301
  • Organization District
    UNITED STATES